What is pathophysiology of Alzheimer?

Wuliriza olupapula luno

Pathophysiology ya alzheimer y'eruwa?

Obusimu bw'obulwadde bwa Alzheimer (AD) buzibu nnyo era butwaliramu okukuŋŋaanyizibwa kw'ebirungo ebitali bya bulijjo, obulumi, n'obutaba na nkola nnungi mu bwongo.

Obubonero obubiri obukulu obw'obulwadde bwa AD kwe kubeerawo kwa amyloid-beta (Aβ) plaques ne neurofibrillary tangles (NFTs) mu bwongo.

Amyloid-beta plaques zikolebwa ng'ebitundu bya amyloid precursor protein (APP) bigabanyizibwamu enzymes ne bifuuka Aβ peptides.

Peptides zino zikwatagana ne zifuula fibrils ezitasobola kusengulwa ezikuŋŋaanira ebweru w'obutoffaali bw'omubiri, ne ziyonoona enkolagana wakati w'obutoffaali n'obutoffaali era ne zireeta okufa kw'obutoffaali bw'omubiri.

Okukuŋŋaanyizibwa kw'ebikoola bya Aβ kitwalibwa okuba ekimu ku bintu ebisookerwako mu kukulaakulana kwa AD, era kitwalibwa okuba nga kiyamba mu nkola ya neurodegenerative.

Neurofibrillary tangles zikolebwa protein tau bw'efuuka hyperphosphorylated era n'etonda obugoye obutali bwa bulijjo munda mu neurons.

Ebisenge bino bikosa enkola ya microtubules, ez'omugaso mu kutambuza ebirungo n'ebintu ebirala mu neuron.

Mu nkomerero, obutoffaali obwo buviirako obutoffaali obwo okufa.

Obulwadde bw'obulwadde bw'obulwadde bw'obulwadde bw'obulwadde bw'obulwadde bw'obulwadde bw'obulwadde.

Enkola y'obulwadde bw'omubiri ekwata ku kuŋŋaanyizibwa kwa Aβ plaques ne NFTs ng'efulumya pro-inflammatory cytokines, ebiyinza okwongera okwonooneka kwa neurons.

Okugatta ku ekyo, waliwo obujulizi obulaga nti obuzibu bwa oxidative stress, mitochondrial dysfunction, ne glucose metabolism ezikyamu zireetawo obulwadde bwa AD.

Ensonga zino ziyinza okuleetawo obunafu bw'obwongo n'okufa, ne zinyweza obulwadde.

Okutwalira awamu, pathophysiology ya AD y'emu ku nsonga ez'enjawulo ezireetawo okukendeera kw'ebikolwa by'okutegeera n'okufiirwa ekijjukizo ekireeta obulwadde buno.

Ebikwata ku bantu

PubMed/Medline https://www.nlm.nih.gov/databases/download/pubmed_medline.html

RefinedWeb https://arxiv.org/abs/2306.01116

Nemeroff CB: The preeminent role of neuropeptide systems in the early pathophysiology of Alzheimer disease: up with corticotropin-releasing factor, down with acetylcholine. Arch Gen Psychiatry. 1999, 56 (11): 991-2.

Skoog I, Kalaria RN, Breteler MM: Vascular factors and Alzheimer disease. Alzheimer Dis Assoc Disord. , 13 Suppl 3 (): S106-14.

Proft J, Weiss N: Jekyll and Hide: The two faces of amyloid β. Commun Integr Biol. 2012, 5 (5): 405-7.

Whitehouse PJ, Hedreen JC, White CL, Price DL: Basal forebrain neurons in the dementia of Parkinson disease. Ann Neurol. 1983, 13 (3): 243-8.

Casadesus G, Moreira PI, Nunomura A, Siedlak SL, Bligh-Glover W, Balraj E, Petot G, Smith MA, Perry G: Indices of metabolic dysfunction and oxidative stress. Neurochem Res. , 32 (4-5): 717-22.

Candore G, Bulati M, Caruso C, Castiglia L, Colonna-Romano G, Di Bona D, Duro G, Lio D, Matranga D, Pellicanò M, Rizzo C, Scapagnini G, Vasto S: Inflammation, cytokines, immune response, apolipoprotein E, cholesterol, and oxidative stress in Alzheimer disease: therapeutic implications. Rejuvenation Res. , 13 (2-3): 301-13.

Raskind MA, Peskind ER: Neurobiologic bases of noncognitive behavioral problems in Alzheimer disease. Alzheimer Dis Assoc Disord. 1994, 8 Suppl 3 (): 54-60.

Schindler SE, McConathy J, Ances BM, Diamond MI: Advances in diagnostic testing for Alzheimer disease. Mo Med. , 110 (5): 401-5.

Singh VK: Immune-activation model in Alzheimer disease. Mol Chem Neuropathol. , 28 (1-3): 105-11.

Okwewala obuvunaanyizibwa: eby'obujjanjabi

Omukutu guno guweereddwa olw'ebigendererwa by'enjigiriza n'obubaka bwokka era teguwa kubuulirira kw'ekisawo oba obuweereza bw'ekikugu.

Obubaka obuweereddwa tebusaanidde kukozesebwa okuzuula oba okujjanjaba bulwadde, era abo abanoonya amagezi g'ekisawo balina okwebuuza ku musawo alina layisensi.

Weetegereze nti enkola ya neural net ekola eby'okuddamu mu bibuuzo, si ntuufu nnyo bwe kituuka ku muwendo gw'abantu. Ng'ekyokulabirako, omuwendo gw'abantu abalwadde obulwadde obumu.

Bulijjo noonya amagezi g'omusawo wo oba omusawo omulala omutuufu ku bikwata ku mbeera y'obulamu. Teweerabira magezi g'omusawo oba okulwawo okuganoonya olw'ekintu ky'osomye ku mukutu guno. Bw'oba olowooza oyinza okuba n'embeera ey'amangu mu by'obulamu, yita 911 oba genda mu ddwaaliro ly'amangu erisinga okumpi amangu ddala. Tewali nkolagana ya musawo n'omulwadde ekolebwa ku mukutu guno oba okukozesawo. BioMedLib oba abakozi baagwo, oba omuntu yenna ayamba ku mukutu guno, talina ky'agamba, ekyogamba oba ekiteeberezebwa, ku bikwata ku bubaka obuli wano oba okukozesawo.

Okwewala obuvunaanyizibwa: eddembe ly'okuwandiika

Digital Millennium Copyright Act ey'omwaka 1998, 17 U.S.C. § 512 (DMCA) ewa abalina eddembe ly'okuwandiika ebitabo abakkiriza nti ebintu ebiri ku mutimbagano bikontana n'eddembe lyabwe wansi w'amateeka g'eddembe ly'okuwandiika ebitabo mu Amerika.

Bw'oba olowooza mu bwesimbu nti ebintu oba ebintu ebikolebwa ku mukutu gwaffe ogwa webusayiti oba obuweereza bikontana n'amateeka go ag'eddembe ly'obuntu, ggwe (oba omubaka wo) osobola okututumira obubaka ng'osaba ebintu oba ebintu ebyo biggyibwe, oba okukugira.

Okumanyisa kulina okusindikibwa mu buwandiike nga bakozesa e-mail (laba ekitundu "Contact" ku adirisa ya e-mail) .

DMCA yeetaaga nti ekiwandiiko kyo eky'okuvumirira obutali bwenkanya bw'eddembe ly'obuntu kitwaliramu obubaka buno: (1) okunnyonnyola omulimu oguli wansi w'eddembe ly'obuntu ogugambibwa obutali bwenkanya; (2) okunnyonnyola ebintu ebigambibwa obutali bwenkanya n'obubaka obumala okutusobozesa okuzuula ebintu ebyo; (3) obubaka bw'okuwuliziganya naawe, nga mw'otwalidde endagiriro yo, ennamba ya ssimu n'ennamba ya e-mail; (4) ekiwandiiko okuva gy'oli ekiraga nti olina okukkiriza okutuufu nti ebintu mu ngeri ey'okwemulugunya tebikkirizibwa nnannyini ddembe ly'obuntu, oba omubaka we, oba mu nkola y'amateeka.

(5) ekiwandiiko ky'oyimirizza, wansi w'omusango gw'okubuusabuusa, nti obubaka obuli mu kiwandiiko kituufu era nti olina obuyinza okussa mu nkola eddembe ly'okuwandiika erigambibwa okuba nga lyamenyebwa;

era (6) omukono ogw'omubiri oba ogw'oku mutimbagano ogwa nnannyini copyright oba omuntu ow'obuyinza okukolera mu linnya lya nnannyini copyright.

Okulemererwa okuteeka obubaka bwonna obuli waggulu kuyinza okuleetawo obudde mu kutambuza okwemulugunya kwo.

Okuwuliziganya

Tukusaba otutumire e-mail n'ebibuuzo / amagezi.

What is pathophysiology of alzheimer?

The pathophysiology of Alzheimer's disease (AD) is a complex process that involves the accumulation of abnormal proteins, inflammation, and neuronal dysfunction.

The two main hallmarks of AD are the presence of amyloid-beta (Aβ) plaques and neurofibrillary tangles (NFTs) in the brain.

Amyloid-beta plaques are formed when fragments of the amyloid precursor protein (APP) are cleaved by enzymes to form Aβ peptides.

These peptides aggregate and form insoluble fibrils that accumulate outside neurons, disrupting cell-to-cell communication and leading to neuronal death.

The accumulation of Aβ plaques is thought to be one of the earliest events in the development of AD, and it is believed to contribute to the neurodegenerative process.

Neurofibrillary tangles are formed when the protein tau becomes hyperphosphorylated and forms abnormal filaments inside neurons.

These tangles disrupt the normal functioning of the microtubules, which are essential for the transport of nutrients and other materials within the neuron.

The tangles eventually lead to the death of the affected neurons.

Inflammation also plays a role in the pathophysiology of AD.

The immune system responds to the accumulation of Aβ plaques and NFTs by releasing pro-inflammatory cytokines, which can exacerbate the damage to neurons.

Additionally, there is evidence that oxidative stress, mitochondrial dysfunction, and impaired glucose metabolism contribute to the pathophysiology of AD.

These factors can lead to neuronal dysfunction and death, further exacerbating the disease process.

Overall, the pathophysiology of AD is a complex interplay of multiple factors that ultimately lead to the progressive decline in cognitive function and memory loss that characterizes the disease.

Disclaimer: medical

This web site is provided for educational and informational purposes only and does not constitute providing medical advice or professional services.

The information provided should not be used for diagnosing or treating a health problem or disease, and those seeking personal medical advice should consult with a licensed physician.

Please note the neural net that generates answers to the questions, is specially inaccurate when it comes to numeric content. For example, the number of people diagnosed with a specific disease.

Always seek the advice of your doctor or other qualified health provider regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. If you think you may have a medical emergency, call 911 or go to the nearest emergency room immediately. No physician-patient relationship is created by this web site or its use. Neither BioMedLib nor its employees, nor any contributor to this web site, makes any representations, express or implied, with respect to the information provided herein or to its use.

Disclaimer: copyright

The Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (the “DMCA”) provides recourse for copyright owners who believe that material appearing on the Internet infringes their rights under U.S. copyright law. If you believe in good faith that any content or material made available in connection with our website or services infringes your copyright, you (or your agent) may send us a notice requesting that the content or material be removed, or access to it blocked. Notices must be sent in writing by email (see 'Contact' section for email address) . The DMCA requires that your notice of alleged copyright infringement include the following information: (1) description of the copyrighted work that is the subject of claimed infringement; (2) description of the alleged infringing content and information sufficient to permit us to locate the content; (3) contact information for you, including your address, telephone number and email address; (4) a statement by you that you have a good faith belief that the content in the manner complained of is not authorized by the copyright owner, or its agent, or by the operation of any law; (5) a statement by you, signed under penalty of perjury, that the information in the notification is accurate and that you have the authority to enforce the copyrights that are claimed to be infringed; and (6) a physical or electronic signature of the copyright owner or a person authorized to act on the copyright owner’s behalf. Failure to include all of the above information may result in the delay of the processing of your complaint.